Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting.

ABSTRACT: BACKGROUND:To evaluate the efficacy and toxicities of regorafenib plus irinotecan, dose-escalated on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping, in previously heavily treated metastatic colorectal cancer (mCRC) and the prognostic values of EGFR expression, KRAS mutations, and tumor sidedness. METHODS:Forty-one patients with mCRC with disease progression after treatment with fluoropyrimidines, oxaliplatin, irinotecan, anti-VEGF, and anti-EGFR MoAbs were subjected to UGT1A1 genotyping and received regorafenib combined with FOLFIRI with dose-escalated irinotecan. RESULTS:The median follow-up period was 10.0?months (1.3-23.5?months). The overall disease control rate was 58.5%, whereas the median progression-free survival (PFS) and overall survival (OS) were 6.0?months and 12.0?months, respectively. KRAS mutations were significantly associated with positive EGFR expression (P?=?.026). KRAS mutations significantly correlated with a shorter OS than KRAS wild-type (6.0 vs. 14.4?months, P?=?.014) but had no significant association with PFS. Positive EGFR expression had an inverse correlation with PFS (2.5 vs. 14.0?months, P?=?.039) and OS (9.6 vs. 19.7?months, P?=?.044). Moreover, left-sided tumors associated with superior PFS (2.0 vs. 7.0?months, P?

SUBMITTER: Ma CJ 

PROVIDER: S-EPMC6307535 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature